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Abstract
To identify novel loci for age at natural menopause, we performed a meta-analysis of 22 genome-
wide association studies in 38,968 women of European descent, with replication in up to 14,435
women. In addition to four known loci, we identified 13 new age at natural menopause loci (P < 5
× 10−8). The new loci included genes implicated in DNA repair (EXO1, HELQ, UIMC1,
FAM175A, FANCI, TLK1, POLG, PRIM1) and immune function (IL11, NLRP11, BAT2). Gene-
set enrichment pathway analyses using the full GWAS dataset identified exodeoxyribonuclease,
NFκB signalling and mitochondrial dysfunction as biological processes related to timing of
menopause.
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Introduction
Menopause is the cessation of reproductive function of the human ovaries. This life stage is
associated with one of the major hormonal changes of women characterized by a decline in
secretion of estrogen, progesterone and, to a lesser degree, testosterone. It influences a
woman’s well-being and is associated with several major age-related diseases including
cardiovascular disease, breast cancer, osteoarthritis, and osteoporosis1. Ovarian aging is
reflected by the continuous decline of the primordial follicle pool, which is established
during fetal life, subsequently leading to endocrine changes due to loss of the negative
feedback from ovarian hormones on the hypothalamic-pituitary axis. In addition to follicle
loss, oocyte quality diminishes with increasing age, which is believed to be due to increased
meiotic nondisjunction2. Oocyte quality may be controlled at the time germ cells are formed
during fetal life, but may also reflect accumulated damage during reproductive life, and/or
age-related changes in granulosa cell-oocyte communication3. Although both oocyte
quantity and quality decline with increasing age, it is not clear whether they are controlled
by the same mechanisms and whether they decline in parallel.
The average age at natural menopause in women of Northern European descent is 50–51
years (range 40–60 years)4. Heritability estimates from twin and family studies for age at
natural menopause range from 44 to 65%5–8. Thus far most genetic association studies
regarding age at menopause have focussed on candidate genes9 from the estrogen
pathway10,11, or vascular components12,13. Recently two genome-wide association studies
(GWAS) identified five novel loci associated with age at natural menopause on
chromosomes 5, 6, 13, 19 and 2014,15. These loci, however, explained <1.5% of the
phenotypic variation of age at natural menopause, suggesting additional loci of small effect
are likely to be discovered in larger samples. Therefore, we conducted a two-stage GWAS
of women of European ancestry, combining the women from the two previous GWAS
studies14,15 with new participants for a total of 38,968 women from 22 studies in the
discovery stage, and 14,435 women from 21 studies in the replication stage.
Results
In our discovery stage of 38,968 women with natural menopause between the ages of 40 and
60 (Supplementary Table 1, Supplementary Table 2), we identified 20 regions with SNPs
meeting the genome-wide significance criterion p<5 × 10−8 (Figure 1a). Four of these loci
confirmed prior reports of associations on chromosomes 5, 6, 19, and 2014,15 (regions 5b,
6a, 19a, and 20, respectively, in Table 1) and 16 loci were novel. We failed to confirm one
previously reported association on chromosome 13 (13q34, rs7333181, p=0.12). The overall
genomic inflation factor was 1.03 (Figure 1b). Table 1 displays the SNP with the lowest p-
value from each region. There was no between-study effect heterogeneity across discovery
studies (p>0.05/20) for the 20 SNP associations presented. Within FHS, we tested for
differences in effect size for the 20 SNPs in retrospectively and prospectively collected
menopause age, and also found no significant differences (data not shown). The effect sizes
ranged from 0.17 years (8.7 weeks) to nearly one year (50.5 weeks) per each copy of the
minor allele. We computed the effect sizes for dichotomized age at natural menopause in the
WGHS women, dichotomizing at age 45 (N=745) versus later for early menopause and at 54
(N=1632) versus earlier for late menopause. The estimated odds ratios for early menopause
for the menopause decreasing allele ranged from 1.01 to 2.03. The estimated odds ratios for
late menopause for the menopause decreasing allele ranged from 0.52 to 0.96
(Supplementary Table 3). The top SNPs in regions 2c, 5a, and 19b were more than 400kb
but less than 1Mb from the top SNP in another region on the same chromosome. The top
SNP in each of these primary regions had low linkage disequilibrium (r2<0.5) with the top
SNP in the nearby region. To determine whether these associations were independent, we
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performed a conditional association analysis in the discovery study samples with the most
significant SNP from each of the primary 17 regions included as covariates in the analysis.
For regions 5a and 19b (rs890835, rs12461110), the effect estimates in the conditional
analysis were unchanged compared to the discovery analysis (differences of 0.3% and 4%,
respectively), and the p-values remained genome-wide significant. However, for region 2c
the effect size was decreased by ~12.5% in the conditional analysis compared to the initial
analysis, and the SNP p-value was no longer genome-wide significant (p=9.8×10−7) (Table
1), suggesting that the association with rs7606918 is not independent of the rs1018348
region 2b association. We attempted replication only for the 19 SNPs that represented
independent regions that reached genome-wide significance (p<5 × 10−8) thus replication of
rs7606918 was not pursued.
Replication
Twenty-one studies contributed 14,435 women for replication of the 19 SNPs defining the
independent genome-wide significant regions from stage 1. Age at natural menopause was
defined using the same criteria as in the discovery studies (Supplementary Table 1).
Seventeen of these studies (N=6,639) were included in in silico replication (Supplementary
Table 2); an additional 4 studies (N=7,796) contributed de novo genotypes for the 19 SNPs
(Supplementary Table 2). Table 1 displays the effect sizes and p-values for replication and a
combined meta-analysis of the discovery and replication samples. There was no evidence for
effect heterogeneity among the replication studies (Table 1). Further, we tested for
heterogeneity between the in silico and de novo genotyped studies, and found no evidence
for heterogeneity of effect (data not shown), suggesting that for the significant SNPs, the
genotype imputation methods did not result in significantly different effect size estimates
than would have been obtained from direct genotyping. Seventeen of the 19 SNPs remained
genome-wide significant and had lower p-values in combined meta-analysis of the discovery
and replication samples. Regions 5a and 13a showed no evidence of association in the
replication samples (p>0.50) and were not genome-wide significant in combined discovery
and replication meta-analysis. Four of the 17 replicated regions were reported previously;
thus our analysis identified 13 novel regions for age at natural menopause based on genome-
wide significant discovery with replication. In the combined discovery and replication meta-
analyses the effect estimates ranged from 8.2 to 49.3 weeks per minor allele. The estimated
proportion of variance explained by the 17 replicated SNPs in the four replication studies
with de novo genotyped SNPs ranged from 2.5% (Osteos) to 3.7% (EPOS and BWHHS) to
4.1% (PROSPECT-EPIC).
We used the largest study contributing data to our discovery GWAS (WGHS, N=11379) to
explore whether substantial SNPxSNP interactions are present among the 17 replicated
SNPs. We tested all 136 pairs of SNPs and found no evidence for interaction (all P>0.01).
Roles of genes at/near novel loci
All but two of the replicated SNPs are intronic or exonic to known genes (Table 2). The top
SNPs in regions 6b, 12, 19b, and 20 are missense polymorphisms. Three of the four were
predicted to have damaging protein function by SIFT16, and one by PolyPhen217. Using
dbSNP and LocusZoom18, we identified the genes underlying the novel top regions. We
used SCAN (see URLs) to identify all genes with SNPs that are in linkage disequilibrium
(LD) (r2>0.5) with our SNPs (Table 2). We identified all SNPs with r2 ≥ 0.8 with our top
SNPs and used several databases to determine if the SNPs were known to be associated with
expression (Table 2).
The strongest novel signal was on chromosome 4 (region 4, rs4693089; P=2.4×10−19). The
SNP is located in an intron of HELQ, the gene that encodes the protein HEL308, which is a
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DNA-dependent ATPase and DNA helicase 19. The second strongest novel signal was on
chromosome 12 (region 12, rs2277339; P=2.5×10−19). This SNP is a non-synonymous
variant in exon 1 of PRIM1. The top SNP was significantly associated with expression of
PRIM1 in visual cortex, cerebellum, and pre-frontal cortex (Table 2).
Several other novel signals are located in introns of genes for which mouse models exist.
These were region 8 in ASH2L (rs2517388; P=9.3×10−15), region 13b in POLG (rs2307449;
P=3.6×10−13) and region 1b in EXO1 (rs1635501; P=8.5×10−10). ASH2L codes for a
trithorax group protein, and is involved in X chromosome inactivation in women20. POLG
encodes the catalytic subunit of mitochondrial DNA polymerase, the enzyme responsible for
replication and repair21 of mitochondrial DNA. EXO1 is a member of the RAD2 nuclease
family of proteins involved in DNA replication, repair and recombination, and the top hit is
in LD (r2=0.83) with a functional polymorphism in EXO1 that affects a transcription factor
binding site in the promoter. Region 11 (rs12294104; P=1.5×10−11) is near and in LD
(r2=0.92) with SNPs in FSHB. Transcription of FSHB limits the rate of production of the
heterodimeric follicle stimulating hormone (FSH), a key pituitary expressed hormone that
stimulates maturation of follicles. Region 19a (rs11668344; P=1.5×10−59) is in tight LD
with SNPs in IL11: this cytokine stimulates the T-cell-dependent development of
immunoglobulin-producing B cells.
The top SNPs in two other novel regions are non-synonymous coding variants. Region 6b,
rs1046089 (P=1.6×10−16) is in exon 22 of BAT2 and was associated with expression of
several transcripts in the HLA region in several tissues (Table 2). Region 19b, rs12461110
(P=8.7 × 10−10) is in exon 5 of NLRP11. BAT2 encodes the gene for HLA-B associated
transcript 2 and has several microsatellite repeats. NLRP11 encodes for the NLR family,
pyrin domain containing 11 protein, which is implicated in the activation of
proinflammatory caspases22.
Of the remaining five novel regions, the top SNPs for regions 1a, 2a, 2b, and 13b are located
in introns. These were rs4246511 in RHBDL2 (0.24 years/minor allele, P=9.1×10−17),
which is thought to function as intramembrane serine proteases, rs2303369 in FNDC4
coding for fibronectin type III domain containing 4 (P=2.3×10−12), rs10183486 in TLK1
(P=2.2×10−14) a nuclear serine/threonine kinases that is potentially involved in the
regulation of chromatin assembly, and rs4886238 in TDRD3 (P=9.5×10−11). TDRD3 is a
known binding partner for FMR1, which has been associated with primary ovarian
insufficiency. The top SNP in the final novel region, 16, is within 60kb of three genes:
TNFRSF17, GSPT1, and RUNDC2A. It is in LD (r2>0.5) with SNPs in these three genes as
well as four others (rs10852344; P=1.0×10−11) (Table 2).
Pathway analyses
We used three independent pathway-based methods to identify connections among our
single marker associations, and link them with broader biological processes. While all three
approaches (Ingenuity Pathway Analysis(IPA, see URLs), MAGENTA23 and GRAIL24) are
based on published data, linking the gene products of our top hits to each other in functional
pathways, each uses substantially different methodology and take different aspects of our
results as input. Thus, we expect complementary results from the three approaches.
We used IPA(See URLs), to identify potential biological pathways common to the 17
replicated SNPs. Based on the genes physically nearest the 17 loci, four major functional
networks were identified based on direct interactions only (Supplementary Table 4).
Network 1, related to “lipid metabolism, molecular transport, and small molecule
biochemistry”, contained 14 of the genes nearest to the menopause loci (P=1×10−30).
Central to this network is the HNF4A gene, which is known to play a role in diabetes.
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Network 2, containing 12 of the input genes, relates to “cell cycle, cell death, and cancer”
(P=1×10−24). The ESR1 gene is central in this network, suggesting that genes in this
network influence or are influenced by estrogen signaling. Network 3, also in part related to
“cell death”, including TNF and NFκB (P=1×10−19). Network 4 relates to “infection
mechanism, DNA replication, recombination, and repair, and gene expression”
(P=1×10−12). Interestingly, several of the input genes included in network 1 (EXO1, HELQ)
and network 2 (UIMC1, FANCI, TLK1) are also involved in DNA repair mechanisms.
We used a gene set enrichment analysis (GSEA) implemented in MAGENTA23 to explore
pathway-based associations using the full GWAS results. Three pathways reached study-
wide significance (FDR < 0.05): exodeoxyribonuclease (P = 0.0005), NFκB signalling (P =
0.0006) and mitochondrial dysfunction (P = 0.0001) (Supplementary Table 5).
Finally, we used the GRAIL method of literature based pathway analysis24 to explore the
connections between the genes near our top SNPs. Genes are considered related if they share
informative words. GRAIL scores for genes associated with 3 of the replicating genome-
wide significant SNPs were significant: EXO1, FKBPL, and BRSK1. When applied to a
deeper set of 66 SNPs from the discovery meta-analysis with significance meeting
FDR<0.05, 12 genes had significant GRAIL scores: EXO1, MSH6, PARL, RHBDL2,
FKBPL, TP53BP1, TLK1, RAD54L, CHEK2, H2AFX, APEX1, REV3L. In addition,
BRSK1 was borderline significant with GRAIL FDR=0.06.
Candidate genes
Within the discovery GWAS 18,327 SNPs were within 60kb of the start and end of
transcription of 125 candidate genes selected because of a reported relationship with ovarian
function (Supplementary Table 6). After multiple testing correction, 101 SNPs in or near
five of the candidate genes (DMC1, EIF2B4, FSHB, POLG, RFPL4A) were significantly
associated with age at natural menopause after multiple testing correction. SNPs in or near
four of these genes were already identified as genome-wide significant (EIF2B4, region 2a;
RFPL4A, region 19b; POLG, region 15; and FSHB, region 11). For the other gene, DMC1,
the most significant SNP was rs763121, with nominal P=1.6×10−7, (P=0.0009 corrected for
candidate gene SNP analyses); age at natural menopause decreases by ~0.18 years per copy
of the minor allele. DMC1 encodes for a protein that is essential for meiotic homologous
recombination and is regulated by NOBOX, mutations in which can cause Primary Ovarian
Insufficiency (POI)25–27
Pleiotropy of primary hits
We examined overlap of our significant regions against published GWAS results for other
traits (GWAS catalog; see URLs). Twelve menopause loci were within 1Mb of a previously
published genome-wide significant SNP, but most of the co-localised SNPs were in low LD
(0 < r2<0.21) with our SNP in the region (Supplementary Table 7). The exception was at the
GCKR locus on chromosome 2. Region 2a (rs2303369) was correlated (r2 ≈0.5) with four
different SNPs reported to influence kidney function, type 2 diabetes, continuous glycaemic
traits, as well as serum albumin, C reactive protein, serum urate, and triglycerides. These
results increase the observed clustering of signals in complex trait genetics, whilst also
adding to the increasing pleiotropy observed at the GCKR locus.
Discussion
In this large 2-stage GWAS we have confirmed four previously established menopause loci
and identified and replicated 13 novel loci associated with age at natural menopause. Of
these 17 hits, all but two are intronic or exonic to known genes. On average for associated
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SNPs in GWAS studies, 40% are intergenic, while only2% of our hits are intergenic.
Further, our study finds two times more non-synonymous top hits as typically seen in
GWAS (24% vs 12%)28. The 17 replicated loci function in diverse pathways including
hormonal regulation, immune function and DNA repair. Together, they explained 2.5–4.1%
of the population variation in menopausal age in independent replication samples. Biological
pathway analysis of the genetic associations with age at natural menopause in this study
using distinct algorithms and databases were in close agreement in emphasizing general
biological pathways for mitochondrial function, DNA repair, cell cycle and cell death, and
immune response.
Aging is thought to result from the accumulation of somatic damage29. Analysis of gene
expression patterns in aging organs, such as heart and brain, identified changes in genes
involved in inflammatory response, oxidative stress, and genome stability30, processes also
identified in analysis of age-related changes in mouse oocytes, including changes in
mitochondrial function31. Comparisons of lifespans across species showed that there is a
general relationship between longevity and DNA repair function32. This notion is reinforced
in the Werner and Bloom syndromes, which involve genome instability due to mutations in
3′–5′ DNA helicases of the RecQ family members, and are characterized by both premature
aging and premature menopause33. Similarly, an increase in meiotic errors is associated with
an age-related decline in oocyte quality, compounding the progress toward menopause due
to follicle depletion34.
In the biological pathways analysis, seven candidate genes identified by proximity to the 17
genome-wide significant associations with age at natural menopause are related to DNA
damage repair and replication (EXO1, HELQ, UIMC1, FAM175A, FANCI, TLK1, POLG,
PRIM1) (Supplementary Table 4). The protein encoded by UIMC1 physically interacts with
BRCA1 and estrogen receptor α (ERα) and is thought to recruit BRCA1 to DNA damage
sites and to initiate G2/M checkpoint control. PRIM1 (Primase) is involved in DNA
replication by synthesising RNA primers for Okazaki fragments during discontinuous
replication35. A mutation in POLG can segregate with primary ovarian insufficiency
(POI)36. Polg knock-in mice show reduced lifespan, premature ageing, and reduced
fertility37. FANCI, as a second gene at the same locus adjacent to POLG, is a member of the
Fanconi anemia (FA) complementation group. FA is a recessive disorder characterized by
cytogenetic instability and defective DNA repair. FA patients experience irregular
menstruations with menopause occurring around the age of 3038. The functional
polymorphism correlated to our top hit in EXO1, has been associated with longevity in
female centenarians39. Male and female Exo1 knock-out mice are sterile, because the gene
is essential for male and female meiosis40. In addition to the GWAS regions in/near genes
previously associated with early menopause, we investigated a panel of candidate genes
identified prior to the study, and found a SNP near the meiotic recombination gene DMC1 to
be significantly associated with age at menopause. How the DNA repair pathways contribute
to menopause remains unclear. It is possible that with altered DNA repair mechanisms
damage accumulates rendering poor quality oocytes for selection. On the other hand, the
number of damaged follicles may increase with ageing, resulting in an increased rate of
follicle loss through atresia. Next to this, our top hit in this study, one of the four known hits,
is a non-synonymous SNP in MCM8, was not included in the IPA results, probably because
the exact function of this protein is still unknown. The MCM family, however, is a key
component of the pre-replication complex and its main function is to restrict DNA
replication to one round per cell cycle41.
The pathway analyses highlighted additional candidate genes with functions in DNA repair
(exodeoxyribonuclease), but with sub-genome-wide levels of significance for association
with age of natural menopause. These 12 candidates (Supplementary Table 5) included the
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Werner (WRN) helicase gene, mutations in which cause Werner syndrome, a classic
progeria with advanced ageing phenotype, and ovarian aging42. Estrogen can enhance WRN
expression preventing cell senescence, suggesting its involvement in menopause43. The
identification of DNA repair as one of the biological pathways involved in menopause may
also provide an explanation for the association between smoking and an earlier age at
menopause. Damage caused by smoking activates several different DNA repair
mechanisms. Indeed, a polymorphism in Exo1, one of our top loci, has been associated with
colorectal adenomas in smokers only44. Future studies will reveal whether smoking status
modifies the association between age at natural menopause and polymorphisms in DNA
repair genes, as has been observed for various cancers.
The pathways-based analysis also emphasized that genes related to auto-immune disease
also influence age at natural menopause. This link has not been reported before, however, in
a proportion (2–10%) of women with POI, ovarian auto-immunity can play a role45. In
addition, POI is frequently associated with additional autoimmune diseases, such as type 1
diabetes mellitus 46. The top SNP in region 19a is near IL11, which binds the IL11 receptor
alpha chain (IL-11Rα). Female mice with null mutations in IL-11Rα are infertile due to
defective uterine decidualization, the process necessary for successful embryo
implantation47. NLRP11 (region 19b) is a member of the NLRP family of genes that play
important roles in the innate immune system and reproductive system. Several NLRP genes
show an oocyte specific expression pattern 46, while NLRP5 has been implicated in POI,
and serves as an autoantigen in a mouse model of autoimmune POI48,49. Many autoimmune
conditions are associated with a particular HLA type, but no such association has been
reported for POI50,51. One of our top menopause associations (rs1046089) is a missense
substitution in BAT2 (HLA-B associated transcript), which is in the HLA class III complex
on chromosome 6 and has been associated with type I diabetes mellitus and rheumatoid
arthritis. Multiple phenotypes have been associated with BAT2 SNPs in GWAS studies
including BMI, neonatal lupus, HIV control and height (Supplementary Table 7), but the
SNPs have low correlation with our top hit. Expression data for rs1046089 demonstrated
that the polymorphism was associated with altered expression of HLA-DRB4 in monocytes
and HLA-DQA1 in lymphoblastoid cell lines (Table 2). Thus, this gene is an excellent
candidate for a pro-inflammatory component to oocyte depletion affecting menopause age.
Indeed, the enrichment of the genes involved in NFκB signalling (TNF, TNFRSF17,
CSNK2B) in the biological pathways analysis suggests that susceptibility to inflammation,
which often accompanies immunosenescence in aging, may also affect ovarian aging. The
finding that the innate immune response can be upregulated in response to DNA damage52
suggests that interplay between the two main pathways we have identified (DNA repair and
inflammation), may contribute to variation in the age at natural menopause.
Three of the 17 regions can be linked to hormonal regulation, an additional route to follicle
pool exhaustion. The top region 11 SNP (rs12294104) is in high LD with SNPs in FSHB
(r2=0.92, Table 2), a gene which limits the rate of production of follicle stimulating hormone
(FSH), a key pituitary expressed hormone that stimulates maturation of follicles. FSH-
deficient female mice are infertile53. Transgenic mice with FSH over-expression show
premature infertility due to postimplantation reduction of embryo-fetal survival54. FSH
concentrations rise in women approaching menopause, which might be related to a decrease
in growing follicles55. Mutations in FSHB cause hypogonadism and primary amenorrhea in
women56 and raised FSH levels and infertility in males57. The latter observation is due to a
promoter polymorphism that may be causal58 and is in LD (r2 = 0.7) with our most
significant SNP. Although STAR, encoding steroidogenic acute regulatory protein (StAR)
was not the nearest gene to the top SNP in region 8 (rs2517388), its functional role in
cleavage of cholesterol to pregnenolone in response to tropic hormones makes it the likely
functional candidate, and our top SNP is in high LD with SNPs in that gene (r2=0.81, Table
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2). Pregnenolone is a precursor for several steroid hormones, such as estrogen and
progesterone, and mutations in the StAR gene are associated with congenital lipoid adrenal
hyperplasia and POI59. Furthermore STAR is a target of FOXL2, for which truncating
mutations are preferentially associated with POI60. Similarly, known biological function
suggests that BCAR4, encoding the breast cancer antiestrogen resistance 4 protein, is the
best candidate gene near region 16. BCAR4 is expressed only in placenta and oocytes and
may play a role in hormonal stimulation in the ovary. In breast cancer treatment, tumours
expressing higher levels of BCAR4 are more resistant to tamoxifen treatment61, reinforcing
its role in transduction of hormonal signals.
In summary, our findings demonstrate the role of genes which regulate DNA repair and
immune function, as well as genes affecting neuroendocrine pathways of ovarian function,
indicating the process of ageing as a shared player in both somatic and germ line ageing.
We expect a substantial number of additional common variants with small effects on ANM
are yet to be identified, and that many of them will be in genes that are in the pathways
identified in this study. Sequencing and exome chip studies to determine whether low
frequency and rare variants of large effect also contribute to ANM are underway or being
planned in many of the cohorts involved in this GWAS. A collaboration of several consortia
is currently examining the contribution of common genetic variants to ANM in African
American (AA) women, and will allow us to determine whether the genetic variation that
affects ANM in AA women are the same or substantially different than for women of
primarily European descent. We are currently conducting a study of women with primary
ovarian insufficiency to determine whether the variants that are associated with ANM within
the normal range also contribute to disease conditions related tothe early menopause
phenotype.
Methods
Discovery
Age at natural menopause was defined as the age at the last menstrual period which occured
naturally with at least 12 consecutive months of amenorrhea. This analysis included women
with natural menopause between the ages of 40 and 60 years. Women of self-reported non-
European ancestry were excluded, as were women with menopause due to hysterectomy
and/or bilateral ovariectomy, or chemotherapy/irradiation, if validated by medical records,
and women using HRT before menopause. Most cohorts collected the age at natural
menopause retrospectively; in the Framingham Offspring, ARIC, NHS and WGHS studies,
some women became menopausal under study observation. Study specific questions, mean
age at menopause and age at interview are shown in Supplementary Table 1. Genotyping
and imputation information for the discovery cohorts are shown in Supplementary Table 2.
Descriptions of each study are in the Supplementary Note.
Replication
A total of 14,435 women from 21 studies meeting the same inclusion and exclusion criteria
as the discovery analysis women were included in the replication analysis. The women had
mean and standard deviation of age at natural menopause similar to the discovery set
(Supplementary Table 1). Genotyping and imputation methods for the in silico replication
cohorts are shown in Supplementary Table 2. Genotyping information for the studies that
genotyped the SNPs de novo is shown in Supplementary Table 2. Descriptions of each study
are in the Supplementary Note.
The 19 independent genome-wide significant SNPs were tested for association with age at
natural menopause using linear regression models.
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Meta-analysis
Inverse variance weighted meta-analysis of the studies was performed using METAL using
genomic control62. A SNP within a study was omitted if the minor allele frequency (MAF)
was < 1% or imputation quality score was < 0.2. The discovery meta-analysis included
2,551,160 autosomal SNPs and 38,968 samples.
eQTL analysis
For each of the genome-wide significant menopause SNPs (Table 1), all proxy SNPs with
r2>0.8 were determined in HapMap CEU release 22. Each SNP and its proxies were
searched against a collected database of expression quantitative trait locus (eQTL) results,
including the following tissues: fresh lymphocytes63, fresh leukocytes64, leukocyte samples
in individuals with Celiac disease65, lymphoblastoid cell lines (LCL) derived from asthmatic
children66, HapMap LCL from three populations67, a separate study on HapMap CEU
LCL68, fibroblasts, T cells and LCL derived from cord blood69, two studies on peripheral
blood monocytes70,71, CD4+ lymphocytes72, adipose and blood samples73, two studies on
brain cortex70,74, three large studies of brain regions including prefrontal cortex, visual
cortex and cerebellum (Emilsson, personal communication), a study of cerebellum, frontal
cortex, temporal cortex and caudal pons75, a separate study on prefrontal cortex76, liver77,
and osteoblasts78. The collected eQTL results met criteria for statistical significance for
association with gene transcript levels as described in the original papers. Table 2 provides a
summary of eQTL findings for replicated GWAS SNPs.
Conditional analysis
On each chromosome, the lowest p-value SNPs that met genome-wide significance were
identified. Genome-wide significant SNPs more than 250,000 base pairs and less than 1
million base pairs apart that also had pairwise HapMap CEU linkage disequilibrium values
of r2<0.5 were considered potentially independent regions. Potential independent regions
that were within 1 million base pairs of a second region with more significant p-value were
tested for independence using conditional analysis. In this analysis, the most significant SNP
in the most significant region on each chromosome was used as a covariate in a genome-
wide analysis. The second region on the chromosome was then re-tested for independent
association.
Pathway analyses
Ingenuity pathway analysis (IPA) Knowledge Base 8.8 (see URLs) was used to explore the
functional relationship between proteins encoded by the 17 replicated menopause loci. The
IPA Knowledge Base contains millions of findings curated from the literature. All reference
genes (n=61) within 60kb potentially encoded by the 17 loci (Table 2) were entered into the
Ingenuity database. Fifty-one genes were eligible for pathway analysis. These eligible ‘focus
genes’ were analyzed for direct interactions only. Networks were generated with a
maximum size of 35 genes and shown as graphical representations of the molecular
relationships between genes or gene products. Proteins are depicted as nodes in various
shapes representing the functional class of the protein. Lines depict the biological
relationships between nodes. To determine the probability of the analyzed gene to be found
together in a network from Ingenuity Pathways Knowledge Base due to random chance
alone, IPA applies a Fisher’s exact test. The network score or p-value represents the
significance of the focus gene enrichment. Enrichment of focus genes to diseases and
functional categories was also evaluated in the IPA Knowledge Base. The p-value, based on
a right-tailed Fisher’s exact test, considers the number of identified focus genes and the total
number of molecules known to be associated with these categories in the IPA knowledge
database.
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MAGENTA was used to explore pathway-based associations in the full GWAS dataset.
MAGENTA implements a GSEA-based approach, the methodology of which has been
previously described23. Briefly, each gene in the genome is mapped to a single index SNP
with the lowest P value within a 110 kb upstream, 40 kb downstream window. This P value,
representing a gene score, is then corrected for confounding factors such as gene size, SNP
density and LD-related properties in a regression model. Genes within the HLA region were
excluded from analysis due to difficulties in accounting for gene density and LD patterns.
Each mapped gene in the genome is then ranked by its adjusted gene score. At a given
significance threshold (95th and 75th percentiles of all gene scores), the observed number of
gene scores in a given pathway, with a ranked score above the specified threshold percentile,
is calculated. This observed statistic is then compared to 1,000,000 randomly permuted
pathways of identical size. This generates an empirical GSEA P value for each pathway.
Significance was determined when an individual pathway reached a false discovery rate <
0.05 in either analysis (Supplementary Table 5). In total, 2,580 pathways from Gene
Ontology, PANTHER, KEGG and Ingenuity were tested for enrichment of multiple modest
associations with age at natural menopause.
GRAIL is designed to provide evidence for related biological function among a set of
candidate genes. The method is based on connections between gene names and informative
words extracted from PubMed abstracts by automated language processing techniques.
Genes are considered related, and achieve a high similarity score, if they share informative
words. For this analysis, the input for GRAIL was a list of candidate SNPs associated with
age at natural menopause. From among candidate genes mapping near the candidate SNPs,
GRAIL identifies genes with associated informative words that are significantly similar to
informative words from other candidate genes. Genes with significant similarity scores are
thus consistent with the set of candidate genes as a whole in having greater sharing of
informative words than expected by chance, which may suggest shared biological functions
or even biological pathways. GRAIL was first applied to the lead SNPs from each of the
replicating genome-wide significant loci using the database of genes and informative words
from 2006. Separately, GRAIL was applied to a list of 66 SNPs, one from each locus that
had at least one SNP meeting a false discovery rate (FDR) threshold of 0.05 from the
QVALUE software in R79. For the age at natural menopause meta-analysis, the FDR < 0.05
threshold implied a p-value < 2.8×10−5.
Candidate gene analysis
We explored the association of natural age of menopause with 125 candidate genes selected
because of a reported relationship with ovarian function, including animal models where
gene mutations affect ovarian function (N=37), human studies of menopause or isolated
primary ovarian insufficiency (N=48), syndromes which include ovarian failure (N=4), or
genes expressed in the ovary or female germ cells (N=38) (see Supplementary Table 6). For
each gene, the start and end of transcription was defined by the transcripts that span the
largest portion of the genome. NCBI36/hg18 positions taken from the UCSC genome
browser were used to define gene and SNP locations. Using the correlation measured from a
set of ~850 independent Framingham Heart Study participants, we computed the effective
number of independent SNPs for each chromosome 80, and used the total (5,774) in a
Bonferroni correction for multiple testing.
Pleiotropy of primary hits
Allelic pleiotropy was explored by comparing the genome-wide significant menopause
signals to the online catalogue of published genome-wide association studies (GWAS
catalog; see URLs). All reported associations that reached P<5×10−8 and were within 1Mb
of the menopause signal were considered. LD estimates between the SNP pairs were
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assessed using HapMap (CEU, release#27). The results are presented in Supplementary
Table 7.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
a. Manhattan plot of discovery meta analysis. b. quantile-quantile plot of discovery primary
analysis (red), and double genomic control adjusted primary analysis (black)
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